# Milad Alucozai

> Milad Alucozai is a seed investor at Revalia Bio backing Biotechnology and Health Care. See 55 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Revalia Bio](https://shizune.co/investors/profile/revalia-bio)
- Location: San Francisco, United States
- Total investments: 55
- Last investment: Jul 2025
- Lead investor: 9%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/miladalucozai/
- X (Twitter): https://twitter.com/MiladAlucozai
- Website: https://www.joinef.com/

Milad Alucozai is a seed investor at Revalia Bio in San Francisco focused on Biotechnology and Health Care. Recognized by Business Insider in 2025 as “one of the top 100 early-stage investors,” Dr. Alucozai has experience translating exceptional science and technology into scalable commercial ventures. Alongside his experience as a founder and operator, he has actively invested in over 100 startups across North America and Europe. He has often been thefirst investor to back high-growth companies like Seqera Labs. Milad began his career as a neuroscientist at the intersection of bioengineering, computational biology, and machine learning, where he commercialized platforms designed to deliver promising medicines to patients more efficiently and safely. His focus as an investor has been to accelerate the journey of groundbreaking discoveries from the lab to the market, particularly in the life sciences sector and related computational fields.Milad is a co-founder and General Partner at Pamir Ventures, an early-stage venture firm that invests in technical pioneers developing B2B companies utilizing AI in antiquated industries. He is also a co-founder of Revalia Bio, which aims to establish a human-centric infrastructure for drug discovery and development. By using non-transplantable human organs donated for research, Revalia offers the scientific community unparalleled insights into patient biology, ultimately aiding in the creation of improved treatments and cures. Throughout his operating and investing career, Milad has played a crucial role in helping founders secure hundreds of millions in capital and facilitating over $1 billion in startup-pharma partnerships. His previous roles include supporting business development at Accenture, Absci, Bit Bio, Numerate, Mekonos, and AstraZeneca. Through Digitalis Commons, he was an Expert in Residence in support of the Advanced Research Projects Agency for Health (ARPA-H), where he aided the US government and ARPA-H mission to enable transformative biomedical and health breakthroughs, providing health solutions through $1.5 billion in non-dilutive investments. He was a National Science Foundation Scholar and Macklin Fellow at Johns Hopkins Medicine. He graduated Phi Beta Kappa with a degree in Neuroscience from Purdue University’s Honors Program, earned a master’s in Immunology and Public Health as a George J. Mitchell Scholar, and holds a doctorate from the Richard M. Fairbanks School of Public Health. Additionally, he completed a Visiting Scholar appointment at the Wyss Institute at Harvard University.

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $1M–$7M |
| Pre-Seed | $110k–$5M |
| Series A | $13M–$60M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 23 | 42% |
| Health Care | 17 | 31% |
| Artificial Intelligence | 7 | 13% |
| Medical | 6 | 11% |
| Life Science | 6 | 11% |

43 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 24 | 44% |
| Series A | 12 | 22% |
| Pre-Seed | 7 | 13% |
| Funding Round | 3 | 5% |
| Series B | 2 | 4% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 26 | 47% |
| Canada | 7 | 13% |
| United Kingdom | 3 | 5% |
| Spain | 1 | 2% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Replit | Replit provides a cloud-based software development platform that allows users to write, run, and deploy applications through a browser-based environment. The platform includes an integrated code editor, terminal, debugging tools, and hosting features that support the creation and deployment of full-stack applications from a single workspace. Replitsupports multiple programming languages and provides preconfigured development environments so projects can start without installing local software.The platform includes collaboration features that enable multiple users to edit and run code within the same project in real time. It also offers AI-assisted coding tools that generate code suggestions, help debug programs, and assist with building applications through natural language prompts. Replit provides project sharing, templates, and integration with external services and repositories to support development workflows. | $250M | Series C | Jul 30, 2025 |  |
| Axonis Therapeutics | Axonis translates breakthrough regeneration research to groundbreaking paralysis therapy, to transform the lives of spinal cord injury patients. | $115M | Series A | Oct 30, 2024 |  |
| Pathway Medical | Pathway is a health tech company working on helping clinicians and patients access important medical information more effectively throughout the care journey. We leverage AI and big data to create a medical knowledge graph and software solutions that drive evidence-based medicine into clinical practice. | $5M | Seed | Nov 10, 2023 |  |
| Revalia Bio | Revalia Bio develops curative drugs for chronic organ-centered disease. | $5M | Pre-Seed | Mar 01, 2023 |  |
| Future Fields | Future Fields is committed to producing sustainable components for science through insect biotechnology. Its EntoEngine™ platform is the first to harness the genetic prowess of fruit flies to produce Earth’s most environmentally and economically sustainable biomolecules. Founded in 2018, Future Fields is headquartered in Edmonton, Canada andproudly backed by marquee venture capital firms and investors from Silicon Valley and beyond. Learn more about how Future Fields is enabling great science at https://futurefields.io/. | $11.1M | Series A | Feb 22, 2023 |  |
| Eigen Therapeutics | Eigen Therapeutics is a biotechnology company on a mission to make therapies that make cancer easier to find and eliminate. Eigen is focused on the development of “priming” therapies, therapies that help targeted therapies reach their full potential by addressing cancer heterogeneity, making cancer cells more vulnerable and/or making healthycells more resilient to treatment. Eigen is building a high-throughput discovery platform to explore the space of priming therapies, leveraging proprietary machine learning algorithms to discover novel associations, new classes of drugs, and new potential therapies that change a cell's state to make it more vulnerable to a targeted therapy. The Eigen platform represents the intersection of biology and engineering, and includes robotic systems, laboratory operations software, and machine learning analysis pipelines—all developed in-house—with the ultimate goal of saving more lives. | $7M | Seed | Dec 08, 2022 |  |
| Wayfinder Biosciences | Wayfinder Biosciences is a biotechnology company developing orally available small molecule drugs that modulate the function of the RNAs encoding key disease targets. The company's proprietary platform combines unique screening and computational technologies to rapidly discover potent, selective and biologically active RNA-targeting smallmolecules. Wayfinder's programs are focused on traditionally inaccessible targets in oncology and neurodegenerative disease. Wayfinder Biosciences was established in 2021 and is headquartered in Seattle, WA. | $3.6M | Seed | Oct 17, 2022 |  |
| Seqera | Seqera Labs is a Barcelona-based business creating solutions for high-performance computing workloads across cloud and clusters. It was founded by the creators of the popular open-source workflow software Nextflow (http://www.nextflow.io). | $21.4M | Series A | Oct 10, 2022 |  |
| Arpeggio Bio | Arpeggio Biosciences leverages state of the art sequencing approaches coupled with powerful machine learning to uncover novel insights into a compound's biological mechanism of action.The company is diverse set of molecular biologists, computer scientists, and biotechnology enthusiasts passionate about understanding where, why, and howtherapeutics work. | $17M | Series A | Sep 07, 2022 |  |
| Notable Labs | Notable Labs is a personalized testing service for cancer patients that prioritizes combinations of FDA-approved treatments that can be immediately prescribed by a doctor without a clinical trial. | $189.2K | Series B | Jul 01, 2022 |  |

10 of 55 investments shown.

## Co-investors
- [Builders VC](https://shizune.co/investors/profile/builders) — VC Fund, 6 deals together
- [10X Capital](https://shizune.co/investors/profile/10x-capital) — VC Fund, 5 deals together
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund, 5 deals together
- [BoxOne Ventures](https://shizune.co/investors/profile/boxone-ventures) — VC Fund, 5 deals together
- [Y Combinator](https://shizune.co/investors/profile/y-combinator) — VC Fund, 5 deals together
- [Bioverge](https://shizune.co/investors/profile/bioverge) — VC Fund, 4 deals together

## About Revalia Bio

VC Fund · New Haven, United States

Revalia Bio develops curative drugs for chronic organ-centered disease.

5 contacts available at Revalia Bio.

| Name | Title | Profile |
| --- | --- | --- |
| Greg Tietjen | Co-Founder and Chief Executive Officer | https://shizune.co/investors/profile/greg-tietjen-7a3f |
| Helen Hughes​ | Co-Founder & Chief Culture & Growth Officer | https://shizune.co/investors/profile/helen-hughes-1d0c |
| Jenna DiRito | Co-Founder & Chief Research Operations Officer | https://shizune.co/investors/profile/jenna-dirito |
| Kourosh Saeb-Parsy | Co-founder and Chief Medical Officer | https://shizune.co/investors/profile/kourosh-saeb-parsy-098a |
| Milad Alucozai | co-founder & Board Member | https://shizune.co/investors/profile/milad-alucozai |

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [BDC Venture Capital](https://shizune.co/investors/profile/bdc-venture-capital) — VC Fund
- [Real Ventures](https://shizune.co/investors/profile/real-ventures) — VC Fund
- [Anges Quebec](https://shizune.co/investors/profile/anges-quebec) — VC Fund

## Featured in investor lists
- [Biotech Angel Investors](https://shizune.co/investors/biotech-angel-investors)
- [Biotechnology Angel Investors](https://shizune.co/investors/biotechnology-angel-investors)
- [Health Care Angel Investors](https://shizune.co/investors/health-care-angel-investors)
- [Health Care Angel Investors in United States](https://shizune.co/investors/health-care-angel-investors-united-states)
- [Biotech Angel Investors in United States](https://shizune.co/investors/biotech-angel-investors-united-states)
- [Life Science Angel Investors](https://shizune.co/investors/life-science-angel-investors)

## FAQ

### What does Milad Alucozai invest in?

Milad Alucozai invests primarily in Biotechnology, Health Care and Artificial Intelligence startups, most often at Seed and Series A stage. Most of the 55 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Milad Alucozai's check size?

Milad Alucozai typically joins rounds of $1M–$7M at Seed, $110k–$5M at Pre-Seed and $13M–$60M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Milad Alucozai participates in.

### When did Milad Alucozai last invest?

The most recent investment recorded for Milad Alucozai closed in Jul 2025. Shizune tracks 55 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co